Introduction
============

A solitary fibrous tumor (SFT) is a rare mesenchymal tumor, which can be found in different locations within the human body ([@b1-ol-0-0-9693]). SFTs were first reported in the pleura and subsequently in the peritoneum, thymus, orbit, pericardium, meninges, spinal cord, and the parotid and thyroid glands ([@b2-ol-0-0-9693]). A tumor of this type in the liver is an extremely rare occurrence. The majority of SFTs are considered benign, while \<20% are reported to be malignant and are accompanied by tumor invasion and metastasis ([@b3-ol-0-0-9693]). Surgical resection is the main approach for SFT treatment. Nevertheless, in certain cases where vascular structures are involved, conventional surgery may not be practical.

*Ex situ* hepatectomy and liver autotransplantation are novel methods for treating complicated liver tumors that are unresectable by conventional approaches, including liver transplantation, vascular reconstruction, organ perfusion, extended hepatic resection and hemodynamic management, which are considered to be some of the most complicated, difficult and risky types of surgeries. In this maneuver, the whole liver is removed and perfused with cold preservation solution. The tumor is resected *ex situ* on the operating table and the remaining liver is orthotopically implanted. The *ex situ* liver resection was first described by Pichlmayr *et al* ([@b4-ol-0-0-9693]) as a novel surgical procedure to treat a bilateral liver leiomyosarcoma. To date, only a few cases of *ex situ* hepatectomy and liver autotransplantation have been described worldwide ([@b5-ol-0-0-9693],[@b6-ol-0-0-9693]). Furthermore, to the best of our knowledge, there are no reports on adopting *ex situ* hepatectomy and liver autotransplantation as an approach for treating hepatic SFTs. The present case study reports the first case of a giant SFT involving the inferior vena cava (IVC) of the liver in a 32-year-old female who was treated with *ex situ* hepatectomy and liver autotransplantation.

Case report
===========

A 32-year-old female suffering from repeated abdominal distension for 3 years was found to have an oversized mass in the right hepatic lobe using a B-scan ultrasound, and was admitted on July 7, 2017 to the Outpatient Department of the First Affiliated Hospital, School of Medicine, Zhejiang University (Hangzhou, China). A physical examination revealed a large mass in the right hypochondrium, causing local discomfort. No aberration was observed regarding the medical history of the patient. In addition, no elevation of tumor markers, including α-fetoprotein (AFP; ARCHITECT AFP Reagent kit; cat. no. 3P36-30; Abbott Pharmaceutical Co., Ltd., Lake Bluff, IL, USA), carcinoembryonic antigen (CEA; ARCHITECT CEA Reagent kit; cat. no. 7K68-32; Abbott Pharmaceutical Co., Ltd.), cancer antigens (CA) 125 (ARCHITECT CA 125 II Reagent kit; cat. no. 2K45-35; Abbott Pharmaceutical Co., Ltd.) and 19-9 (ARCHITECT CA 19-9 *XR* Reagent kit; cat. no. 2K91-38; Abbott Pharmaceutical Co., Ltd.), was observed, as detected using immunofluorescence assays, according to the manufacturers protocols. Hepatitis virus markers were all negative, as detected using an immunofluorescence assay (ARCHITECT Reagent kits; cat. nos. 6C36-44, 8L44-30, 6C34-35, 6C32-20 and 7C18-34; Abbott Pharmaceutical Co., Ltd.), according to the manufacturers protocol. The patient underwent an enhanced abdominal computed tomography (CT) scan, which revealed a giant, hypodense, heterogeneous, cystic-solid lesion (20.0×16.0 cm), with irregular contrast enhancement, causing compression of neighboring structures. Dilation of the intrahepatic biliary ducts was also noted ([Fig. 1](#f1-ol-0-0-9693){ref-type="fig"}). A CT arteriography scan showed that the mass was supplied with blood by the left and right hepatic arteries. The right, middle and left hepatic veins were compressed by the mass and there was indication of a filling defect in the IVC. A magnetic resonance imaging scan was also performed, revealing an oversized, heterogeneous liver mass (21.2×19.7 cm). A heterogeneous high signal in the T2-weighted image and a slightly low signal in the T1-weighted image were observed. All results indicated that the lesion was malignant and a mesenchymal tumor was suspected.

In view of the young age of the patient, an *ex situ* hepatectomy and liver autotransplantation were performed on October 17, 2017. During the surgery, the second hepatic portal was difficult to expose and the sternum was therefore removed with the assistance of a cardiothoracic expert. An intra-operative frozen section examination indicated the proliferation of fibrotic tissue, and the tumor was considered to be benign. Consequently, the tumor was resected on the bench. A 26-mm artificial blood vessel was utilized to establish an end-to-side portocaval shunt during the anhepatic period and the liver remnant was autotransplanted in a piggyback fashion. The surgery was without complications and lasted for 18 h, with an anhepatic period of 5 h.

The resected specimen was well-delimited and measured 19.0×19.5×14.0 cm in size and 3.964 kg in weight. The tumor presented with a grayish-white interlaced appearance in the section plane, and was comprised of spindle-shaped cells infiltrated with lymphocytes, plasmocytes and mastocytes ([Fig. 2](#f2-ol-0-0-9693){ref-type="fig"}). The immunohistochemical (IHC) examination was performed on paraffin-embedded specimens fixed in 4% buffered neutral formalin at 37°C for 24 h. Paraffin-embedded sections (3 µm) were deparaffinized and and endogenous peroxidase was inactivated with 15% H~2~O~2~-Methanol for 5 min at room temperature. The sections were then incubated with primary antibodies at 37°C for 30 min, according to the manufacturers protocols. Subsequently, the sections were incubated with Dako REALREEnVision Detection system, Peroxidase/DAB, Rabbit/Mouse (cat. no. K5007; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) for 30 min at room temperature. Results revealed that the sections were positive for cluster of differentiation 117 (CD117; cat. no. 790-2951; dilution 1:100; Roche Diagnostics, Basel, Switzerland), CD34 (cat. no. M-0117; dilution 1:50; Shanghai Changdao Biotechnology Co., Ltd., Shanghai, China) and Caldesmon (cat. no. ZA-0535; dilution 1:100; OriGene Technologies, Inc., Beijing, China). In addition focal expression of smooth muscle actin (cat. no. ZM-0003; dilution 1:100; OriGene Technologies, Inc.) and progestrone receptor (cat. no. NCL-L-PGR-312; dilution 1:300; Leica Biosystems, Ltd., Milton Keynes, UK) expression was detected. However, sections were negative for S-100 protein (cat. no. ZA-0225; dilution 1:200; OriGene Technologies, Inc.), desmin (cat. no. ZM-0091; dilution 1:100; OriGene Technologies, Inc.), deletions of G-rich-1 (cat. no. ZM-0371; dilution 1:200; Zhongshanjinqiao Bio-Reagent Company), cytokeratin (cat. no. M-0349; dilution 1:100; Shanghai Changdao Biotechnology Co., Ltd.), β-catenin (cat. no. ZM-0442; dilution 1:100; OriGene Technologies, Inc.), anaplastic lymphoma kinase (cat. no. ALK-L-CE-H; dilution 1:150; Leica Biosystems, Ltd.), estrogen receptor (cat. no. NCL-L-ER-6F11; dilution 1:100; Leica Biosystems, Ltd.), epithelial membrane antigen (cat. no. ZM-0095; dilution 1:200; Zhongshanjinqiao Bio-Reagent Company), wilms tumor type 1 (cat. no. ZM-0269; dilution 1:100; Zhongshanjinqiao Bio-Reagent Company) and CD10 (cat. no. NCL-L-CD10-270; dilution 1:100; Leica Biosystems, Ltd.). The sections were evaluated under a light microscope at ×200 magnification. The mean proliferative index was 5% in the hypercellular areas, as determined by detection of antigen KI-67 (Ki-67; cat. no. ZM-0166; dilution 1:100; Zhongshanjinqiao Bio-Reagent Company). The Ki-67 proliferative index was examined under a light microscope (BX53; Olympus Corporation, Tokyo, Japan), and was evaluated by experienced pathologists. A total of 500 tumor cells were counted both at the center and at the periphery of the tumor. The examination was repeated at least twice and the mean Ki-67 proliferative index was calculated. At least 10 mm of the margins of the resected specimen were tumor-free. Based on the pathological and IHC characteristics, the lesion was identified as an SFT.

On post-operative day 9, the patient underwent pleurocentesis and received drainage tubes due to moderate right pleural effusion, which were successfully removed 16 days later. The patient recovered fully and was discharged on post-operative day 29. At the 1- and 3-month follow-ups, the patient had normal liver function and there was no evidence of recurrence. Future follow-up will be performed every 6 months.

Discussion
==========

SFTs are mesenchymal neoplasms that typically occur in the thoracic or pleural cavities. The SFTs found in the liver may derive from the intra-hepatic connective tissue, for example Glisson\'s capsule or conjunctive tissue, which are rare types of liver neoplasm ([@b7-ol-0-0-9693]). A search of the English literature on 'Solitary Fibrous Tumour of the Liver' was conducted on PubMed (<https://www.ncbi.nlm.nih.gov/pubmed/>) and Google (<https://www.google.com/>). All published English articles, case reports and literature reviews, and their reference lists, were reviewed. The results indicated that only 88 cases of SFTs of the liver have been reported since 1958 ([@b7-ol-0-0-9693]--[@b71-ol-0-0-9693]). The main characteristics of these cases are listed in [Table I](#tI-ol-0-0-9693){ref-type="table"}. The mean age of onset was 57.1 years (range, 16.0--87.0 years) and the lesion appeared more commonly in female patients (ratio 1.4:1), with a mean tumor diameter of 18.2 cm (range, 1.5--30.0 cm). The median follow-up time for these cases was 13.5 months. The prolonged course and biological features of SFTs resulted in a relatively late age of onset and large lesion size. The patient in the present study was a 32-year-old female with a single lesion measuring \~19.0 cm; these characteristics were consistent with the cases listed in [Table I](#tI-ol-0-0-9693){ref-type="table"}.

Due to the lack of overt or specific symptoms, patients with SFTs are usually diagnosed coincidentally during a check-up or at a late stage when masses are large enough to produce discomfort by invading or compressing adjacent structures. In the present case, the patient had complained of repeated abdominal distension for 3 years due to the compression of neighboring structures by the lesion. With the exception of the presence of non-islet cell tumor hypoglycemia syndrome observed in 13 cases ([@b9-ol-0-0-9693],[@b16-ol-0-0-9693],[@b17-ol-0-0-9693],[@b19-ol-0-0-9693],[@b22-ol-0-0-9693],[@b25-ol-0-0-9693],[@b28-ol-0-0-9693],[@b31-ol-0-0-9693],[@b36-ol-0-0-9693],[@b48-ol-0-0-9693],[@b60-ol-0-0-9693],[@b69-ol-0-0-9693],[@b70-ol-0-0-9693]), the results of laboratory tests for routine biochemical parameters, including aminotransferases or tumor markers, appear normal or slightly, non-specifically altered ([@b33-ol-0-0-9693]), as was the case with the present patient. Although imaging tests can provide physical characteristics of lesions for clinical analysis, including location and size, the radiological features of an SFT lack specificity, suggesting that none of the aforementioned tests are conclusive.

The gold standard for diagnosing an SFT remains as histopathological analysis combined with IHC examination. Fine-needle aspiration cytology (FNAC) is commonly performed to acquire lesion tissue for pathological diagnosis prior to surgery. Nevertheless, FNAC may be misleading or inconclusive pertaining to the diagnosis of an SFT ([@b37-ol-0-0-9693]). Percutaneous liver biopsy may not provide the definitive diagnosis, while increasing the risk of tumor growth and implantation ([@b53-ol-0-0-9693]). Histopathological findings in the present case were typical for an SFT: Diffusive proliferation of spindle-shaped mesenchymal cells with oval-fusiform nuclei along with fibrocollagenous stroma; no prominent cellular atypia, infiltrative margins or other indicative evidence of malignancy; and tumor cells of all reported cases with an SFT, including the present case, were positive for CD34, which may differentiate an SFT from other spindle cell neoplasms ([@b12-ol-0-0-9693]). CD99, B-cell lymphoma 2 or vimentin have also shown to be positive in almost half the cases ([@b14-ol-0-0-9693]--[@b19-ol-0-0-9693]--[@b21-ol-0-0-9693],[@b24-ol-0-0-9693]--[@b27-ol-0-0-9693],[@b29-ol-0-0-9693]--[@b33-ol-0-0-9693],[@b36-ol-0-0-9693]--[@b48-ol-0-0-9693],[@b50-ol-0-0-9693],[@b52-ol-0-0-9693]--[@b71-ol-0-0-9693]).

Radical surgical resection is the main treatment approach. Among the reported cases listed in [Table I](#tI-ol-0-0-9693){ref-type="table"}, 85.2% (75/88) patients received radical surgical resection and on average had ≥3 segments removed owing to the size of the SFTs. Other treatments, such as chemotherapy, which was adopted recently in two patients listed in [Table I](#tI-ol-0-0-9693){ref-type="table"}, resulted in only 4--5 months survival following treatment. Therefore, Makino *et al* ([@b67-ol-0-0-9693]) suggested that due to the unclear effects of other treatments, including chemotherapy and radiotherapy, hepatic resection with clear margins is highly recommended in patients with large SFTs, considering the risk of urgent symptoms and the potential for malignancy. Compared with the previously reported cases, the tumor reported in the present study was difficult to resect using the conventional approach due to the advanced extent of the lesion therefore, novel techniques may be required.

Even with the vast improvement of surgical techniques, hepatic lesions abutting hepatic veins or the confluence of the IVC, as well as large centrally located lesions, fail to be managed by conventional surgery. In such cases, liver transplantation may be indicated ([@b26-ol-0-0-9693]). However, no liver transplantations have been performed to date for treating SFTs. In the present case, the second hepatic portal was compressed by the neoplasm, causing obstruction of the outflow tract and liver congestion. Full exposure of the second hepatic portal was achieved only after the sternum was removed. The vascular reconstruction and extended hepatic resection were extremely difficult to achieve by *in situ* surgical resection. Given the young age of the patient, the alternative of *ex situ* hepatectomy and liver autotransplantation was implemented. The surgery was performed successfully and the patient recovered without further complications. To the best of our knowledge, this is the first case report describing the adoption of *ex situ* hepatectomy and liver autotransplantation to treat a liver SFT, otherwise unresectable by standard surgery.

The *ex situ* hepatectomy and liver autotransplantation was initially performed by Pichlmayr *et al* ([@b4-ol-0-0-9693]) in 1988 for treating liver tumors involving major vascular structures. The procedure has progressed and developed over the past 30 years, and has been successfully applied for the treatment of several types of lesions, including hepatocellular carcinoma ([@b72-ol-0-0-9693],[@b73-ol-0-0-9693]), hilar cholangiocarcinoma ([@b74-ol-0-0-9693]), giant hepatic hemangiomas ([@b75-ol-0-0-9693]) and metastatic colon cancer ([@b72-ol-0-0-9693],[@b73-ol-0-0-9693],[@b76-ol-0-0-9693]). The reported cases are listed in [Table II](#tII-ol-0-0-9693){ref-type="table"}. The median follow-up and survival times for these cases were 13 and 25 months, respectively. In addition, 63.6% (28/44) patients receiving *ex situ* hepatectomy and liver autotransplantation were \<55 years old, as was the patient reported in the present case. The common indications for this method are major vein involvement and extensive resection area, both of which were noted in the present case. Compared with conventional liver resection, *ex situ* hepatectomy and liver autotransplantation markedly improve the rate of successful resection and clear margins of the otherwise unresectable lesions. There is no long waiting time for a suitable allograft, as an autologous liver is implanted. In addition, the total cost is lower and no post-operative immunosuppressants are required for patients receiving *ex situ* hepatectomy and liver autotransplantation, compared with an allograft liver transplantation ([@b5-ol-0-0-9693]).

The successful establishment of venous reflux and hypothermic perfusion of the isolated liver are essential for securing a successful surgery and a good prognosis ([@b77-ol-0-0-9693]). As the liver resection and trimming surgery are time-consuming, the prolonged anhepatic phase can lead to hemodynamic or internal environmental disturbances. Therefore, in the present case, an artificial blood vessel was used to establish an end-to-side portocaval shunt in order to maintain the venous return of the intestinal tract and lower limbs during the anhepatic period. Compared with autologous vessels, including the great saphenous vein, use of an artificial blood vessel minimizes the invasiveness of the procedure for the patient. As the shunt is temporary, the potential tissue rejection is of no concern.

The commonly encountered complications of *ex situ* hepatectomy and liver autotransplantation include bile leakage, bleeding, pulmonary infection, pneumonedema, hydrothorax and renal insufficiency, with a total incidence of 58.1%. The overall mortality rate within 90 days after surgery is 19.5% ([@b5-ol-0-0-9693]). In the present study, the patient presented with moderate right pleural effusion following surgery, and recovered fully following pleurocentesis and drainage. No other severe complications were encountered up to 3 months after surgery.

In conclusion, this is the first report that describes the successful adoption of *ex situ* hepatectomy and liver autotransplantation for treating an otherwise unresectable giant SFT. The uneventful surgical course and post-operative period suggested that this procedure was suitable for managing an unresectable liver neoplasm. Furthermore, the artificial blood vessels may provide a reliable source for establishing an end-to-side portocaval shunt during the anhepatic period.
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![Abdominal computed tomography scan prior to surgery and gross examination of the specimen. Abdominal computed tomography scans \[(A) plain, (B) arterial and (C) portal phase\] revealed a large, hypodense, heterogeneous, cystic-solid lesion measuring 20.0×16.0 cm, with irregular contrast enhancement, causing compression of the neighboring structures. (D) The resected specimen was well-delimited and measuring \~19×19.5×14 cm, with a grayish-white interlaced appearance of the section plane.](ol-17-01-1042-g00){#f1-ol-0-0-9693}

![Histological examination showed that the tissues consisted of spindle-shaped cells that were infiltrated with lymphocytes, plasmocytes and mastocytes. The images are of hematoxylin and eosin staining at (A) ×50, (B) ×100, (C) ×200 and (D) ×400 magnification.](ol-17-01-1042-g01){#f2-ol-0-0-9693}

###### 

Main characteristics of reported liver solitary fibrous tumor cases.

  First author, year                Age, years   Sex   Lobe   Size, cm       Hypo   Treatment                                           IHC                                              Follow-up                   (Refs.)
  --------------------------------- ------------ ----- ------ -------------- ------ --------------------------------------------------- ------------------------------------------------ --------------------------- ----------------------
  Edmondson, 1958                   16           F     R      23×17          N      Resection                                           N/A                                              24 months                   ([@b8-ol-0-0-9693])
                                    N/A          N/A   R      5×5            N      Resection                                           N/A                                              N/A                         
  Nevius and Friedman, 1959         56           M     R      15×15          Y      Radiation                                           N/A                                              Succumbed after 2 days      ([@b9-ol-0-0-9693])
  Ishak, 1976                       62           M     L      24             N      Resection                                           N/A                                              N/A                         ([@b10-ol-0-0-9693])
                                    62           F     L      23×20×13       N      Resection                                           N/A                                              Succumbed during surgery    
  Kim and Damjanov, 1983            27           F     L      27×23×15       N      Resection                                           N/A                                              6 months                    ([@b11-ol-0-0-9693])
  Kottke-Marchant *et al*, 1989     84           F     L      15×9×8         N      Resection                                           V^+^                                             29 months                   ([@b12-ol-0-0-9693])
  Kasano *et al*, 1991              39           F     L      18×10×18       N      Resection                                           N/A                                              53 months                   ([@b13-ol-0-0-9693])
  Barnoud *et al*, 1996             50           M     R      17×15×11       N      Resection                                           CD34^+^, V^+^                                    N/A                         ([@b14-ol-0-0-9693])
  Levine and Rose, 1997             57           M     L      10×18×8        N      Resection                                           CD34^+^, V^+^                                    38 months                   ([@b15-ol-0-0-9693])
  Guglielmi *et al*, 1998           61           F     R      20×16×10       Y      Resection                                           CD34^+^, V^+^                                    72 months                   ([@b16-ol-0-0-9693])
  Lecesne *et al*, 1998             69           F     L      N/A            N      Resection                                           CD34^+^, V^+^                                    12 months                   ([@b17-ol-0-0-9693])
  Bejarano *et al*, 1998            49           M     L      17×12×10       N      Resection                                           CD34^+^, V^+^                                    15 months                   ([@b18-ol-0-0-9693])
  Moran *et al* 1998                62           F     N/A    23×20×13       N      Resection                                           CD34^+^, V^+^                                    N/A                         ([@b19-ol-0-0-9693])
                                    34           F     N/A    2×0.5          N      Nil                                                 N/A                                              Incidental (autopsy)        
                                    57           F     N/A    24×19×11       N      Resection                                           CD34^+^, V^+^                                    N/A                         
                                    32           M     N/A    12×9×7         N      Resection                                           CD34^+^, V^+^                                    N/A                         
                                    68           F     N/A    17×17          N      Resection                                           CD34^+^, V^+^                                    Succumbed after 2 days      
                                    83           F     R      18             Y      Resection                                           CD34^+^, V^+^                                    Succumbed after 6 days      
                                    72           F     L      9              N      Resection                                           CD34^+^, V^+^                                    12 months                   
                                    62           M     L      24             N      Resection                                           CD34^+^, V^+^                                    N/A                         
                                    50           F     N/A    3×2×1.5        N      Resection                                           CD34^+^, V^+^                                    N/A                         
  Fuksbrumer *et al*, 2000          40           F     R      14--17         N      Resection                                           CD34^+^, V^+^, Bcl-2^+^                          N/A                         ([@b20-ol-0-0-9693])
                                    71           F     R      14--17         N      Resection                                           CD34^+^, V^+^, Bcl-2^+^                          N/A                         
                                    80           M     R      14--17         N      Nil                                                 CD34^+^, V^+^, Bcl-2^+^                          N/A                         
  Yilmaz *et al*, 2000              25           F     R      32×30          N      Resection                                           V^+^                                             6 months                    ([@b21-ol-0-0-9693])
  Lin *et al*, 2001                 75           M     R      21×20×18       Y      Resection                                           CD34^+^                                          11 months                   ([@b22-ol-0-0-9693])
  Gold *et al*, 2002                N/A          N/A   N/A    N/A            N      N/A                                                 N/A                                              N/A                         ([@b23-ol-0-0-9693])
                                    N/A          N/A   N/A    N/A            N      N/A                                                 N/A                                              N/A                         
  Neeff *et al*, 2004               63           F     R      30×12×19       N      Resection                                           CD34^+^, V^+^                                    6 months                    ([@b24-ol-0-0-9693])
  Chithriki *et al*, 2004           76           F     R      20×15×16       Y      Resection                                           CD34^+^, Bcl-2^+^                                11 months                   ([@b25-ol-0-0-9693])
  Vennarecci *et al*, 2005          65           M     R      30×28×14       N      Resection                                           CD34^+^, V^+^                                    30 months                   ([@b26-ol-0-0-9693])
  Moser *et al*, 2005               73           F     R      35×20×15       Y      Resection                                           CD34^+^, V^+^, Bcl-2^+^                          N/A                         ([@b27-ol-0-0-9693])
  Ji *et al*, 2006                  42           F     R      6×5×5          Y      Resection                                           CD34^+^                                          N/A                         ([@b28-ol-0-0-9693])
  Lehmann *et al*, 2006             63           F     R      N/A            N      Resection                                           CD34^+^                                          96 months                   ([@b7-ol-0-0-9693])
  Nath *et al*, 2006                61           F     R      21×14.5×30     N      Resection                                           CD34^+^, V^+^                                    10 months                   ([@b29-ol-0-0-9693])
  Terkivatan *et al*, 2006          74           M     L      24×21×15       N      Resection                                           CD34^+^, CD99^+^, V^+^, Bcl-2^+^                 12 months                   ([@b30-ol-0-0-9693])
  Chan *et al*, 2007                70           M     R      27×24×12       Y      Resection                                           CD34^+^, CD99^+^, V^+^, Bcl-2^+^                 9 months                    ([@b31-ol-0-0-9693])
  Obuz *et al*, 2007                52           M     L      10×11×12       N      Resection                                           CD34^+^, V^+^                                    22 months                   ([@b32-ol-0-0-9693])
  Perini *et al*, 2008              40           F     L      N/A            N      Resection                                           CD34^+^, V^+^                                    49 months                   ([@b33-ol-0-0-9693])
  Weitz *et al*, 2007               N/A          N/A   N/A    N/A            N      Resection                                           N/A                                              N/A                         ([@b34-ol-0-0-9693])
                                    N/A          N/A   N/A    N/A            N      Nil                                                 N/A                                              N/A                         
                                    N/A          N/A   N/A    N/A            N      Nil                                                 N/A                                              N/A                         
  Kandpal *et al*, 2008             45           F     R      N/A            N      Resection                                           CD34^+^                                          N/A                         ([@b35-ol-0-0-9693])
  Fama *et al*, 2008                68           M     R      N/A            Y      Resection                                           CD34^+^, V^+^                                    25 months                   ([@b36-ol-0-0-9693])
  Korkolis *et al*, 2008            82           F     L      18×15×8        N      Resection                                           CD34^+^, V^+^, Bcl-2^+^, desmin^+^               21 months                   ([@b37-ol-0-0-9693])
  Chen *et al*, 2008                71           M     R      8.7×5.5×8.5    N      Resection                                           CD34^+^, CD99^+^, Bcl-2^+^                       9 months                    ([@b38-ol-0-0-9693])
  El-Khouli *et al*, 2008           68           F     L, R   15×10.5×13     N      TACE                                                CD34^+^, V^+^                                    N/A                         ([@b39-ol-0-0-9693])
  Hoshino *et al*, 2009             30           F     R      6.7×4.5×4      N      Nil                                                 CD34^+^, Bcl-2^+^                                6 months                    ([@b40-ol-0-0-9693])
  Novais *et al*, 2010              34           F     R      25×23×13       N      Resection                                           CD34^+^, V^+^                                    24 months                   ([@b41-ol-0-0-9693])
  Brochard *et al*, 2010            54           M     R      17             N      Resection                                           CD34^+^, V^+^, desmin^+^, actin^+^               72 months                   ([@b42-ol-0-0-9693])
  Haddad *et al*, 2010              62           M     L      N/A            N      Resection                                           CD34^+^                                          N/A                         ([@b43-ol-0-0-9693])
                                    45           F     R      7.4×5.9×5.4    N      Resection                                           CD34^+^, V^+^, Bcl-2^+^                          N/A                         
  Park *et al*, 2011                51           F     L      N/A            N      Resection                                           N/A                                              N/A                         ([@b44-ol-0-0-9693])
  Peng *et al*, 2011                24           F     R      30×17×15       N      Resection                                           CD34^+^, V^+^, Bcl-2^+^                          Succumbed after 16 months   ([@b45-ol-0-0-9693])
  Sun *et al*, 2011                 59           M     L      9×7×6          N      Resection                                           CD34^+^, CD99^+^, V^+^, Bcl-2^+^                 24 months                   ([@b46-ol-0-0-9693])
  Patra *et al*, 2012               34           F     L      14.5×10×8      N      Resection                                           CD34^+^, V^+^, Bcl-2^+^                          48 months                   ([@b47-ol-0-0-9693])
  Radunz *et al*, 2012              85           F     L      N/A            Y      Resection                                           CD34^+^, Bcl-2^+^                                N/A                         ([@b48-ol-0-0-9693])
  Belga *et al*, 2012               66           F     R      N/A            N      Resection                                           CD34^+^                                          30 months                   ([@b49-ol-0-0-9693])
  Morris *et al*, 2012              23           F     R      27× 23.5×4     N      Resection                                           CD34^+^, V^+^, Bcl-2^+^                          10 months                   ([@b50-ol-0-0-9693])
  Beyer *et al*, 2012               46           M     RLig   21×7           N      HRT, chemo therapy, resection                       CD34^+^                                          10 months                   ([@b51-ol-0-0-9693])
  Soussan *et al*, 2013             64           M     L      N/A            N      Resection                                           CD34^+^, Bcl-2^+^                                N/A                         ([@b52-ol-0-0-9693])
  Liu *et al*, 2013                 42           M     L      1.5×1×1        N      Resection                                           CD34^+^, Bcl-2^+^                                N/A                         ([@b53-ol-0-0-9693])
  Jakob *et al*, 2013               62           F     L      N/A            N      Resection                                           CD34^+^, CD99^+^, Bcl-2^+^                       N/A                         ([@b54-ol-0-0-9693])
  Debs *et al*, 2014                65           M     L      N/A            N      Resection                                           CD34^+^, CD99^+^, Bcl-2^+^                       12 months                   ([@b55-ol-0-0-9693])
                                    87           F     R      14.6×12.3×17   N      Nil                                                 N/A                                              10 months                   
  Guray-Durak *et al*, 2013         38           F     L      8×6×2          N      Resection                                           CD34^+^, CD99^+^, SMA^+^                         N/A                         ([@b56-ol-0-0-9693])
  Vythianathan and Jim, 2013        78           M     L      17×13          N      Resection                                           CD34^+^, CD99^+^, V^+^, Bcl-2^+^                 N/A                         ([@b57-ol-0-0-9693])
  Song *et al*, 2014                49           M     L, R   7.6×5×4.8      N      Resection                                           CD34^+^, V^+^, Bcl-2^+^                          3 months                    ([@b58-ol-0-0-9693])
  Texeira *et al*, 2014             68           F     L      7.5×6.5×5.5    N      Resection                                           CD34^+^, V^+^                                    28 months                   ([@b59-ol-0-0-9693])
  Du *et al*, 2015                  55           F     L      11×17×15       Y      Resection                                           CD34^+^, Bcl-2^+^                                60 months                   ([@b60-ol-0-0-9693])
  Beltran, 2015                     58           M     L      15×9×6         N      Resection                                           CD34^+^, V^+^                                    36 months                   ([@b61-ol-0-0-9693])
  Bejarano-Gonzalez *et al*, 2015   79           F     R      15             N      TACE, resection                                     CD34^+^, V^+^, Bcl-2^+^                          31 months                   ([@b62-ol-0-0-9693])
  Feng *et al*, 2015                51           M     R      2.3×0.3        N      Resection                                           CD34^+^, Bcl-2^+^                                11 months                   ([@b63-ol-0-0-9693])
                                    49           M     L      8.7            N      Resection                                           CD34^+^, V^+^, Bcl-2^+^                          17 months                   
                                    51           F     R      8.4            N      Resection, adjuvant chemotherapy                    CD34^+^, V^+^, Bcl-2^+^                          31 months                   
                                    52           F     R      12             N      Resection, MWA                                      CD34^+^, V^+^                                    37 months                   
  Silvanto *et al*, 2015            65           M     L      18             N      Resection                                           CD34^+^, CD99^+^, Bcl-2^+^                       16 months                   ([@b64-ol-0-0-9693])
  Kueht *et al*, 2015               40           M     L      4.7×4×4        N      Resection                                           CD34^+^, CD99^+^, V^+^, Bcl-2^+^                 N/A                         ([@b65-ol-0-0-9693])
  Maccio *et al*, 2015              74           F     R      24×16          N      Resection                                           CD34^+^, V^+^, Bcl-2^+^, STAT6^+^                Succumbed after 15 months   ([@b66-ol-0-0-9693])
                                    80           F     R      19×15          N      Chemotherapy                                        CD34^+^, V^+^, Bcl-2^+^, STAT6^+^                Succumbed after 4 months    
                                    65           M     R      3×2            N      Chemotherapy                                        CD34^+^, V^+^, Bcl-2^+^, STAT6^+^                Succumbed after 5 months    
  Makino *et al*, 2015              55           M     R      8.6×6.3        N      Resection                                           CD34^+^, CD99^+^, Bcl-2^+^                       11 months                   ([@b67-ol-0-0-9693])
  Dey *et al*, 2016                 56           F     R      23×22×10       N      Resection                                           CD34^+^, V^+^, Bcl-2^+^                          6 months                    ([@b68-ol-0-0-9693])
  Degnan *et al*, 2016              39           M     L      20×18×15       Y      Resection                                           CD34^+^, V^+^, Bcl-2^+^, STAT6^+^                6 months                    ([@b69-ol-0-0-9693])
  Macak *et al*, 2016               64           N/A   R      20×14.6×19     Y      Resection, TACE                                     NSE^+^, CD34^+^, V^+^, Bcl-2^+^, STAT6^+^        N/A                         ([@b70-ol-0-0-9693])
  Chen and Slater, 2017             61           M     R      15×11.5×7.5    N      Resection                                           CD34^+^, CD99^+^, Bcl-2^+^                       74 months                   ([@b71-ol-0-0-9693])
  Present case                      32           F     L, R   19×19.6×14     N      Ex situ hepatectomy and liver autotransplantation   CD34^+^, CD117^+^, Caldesmon^+^, SMA^+^, PR^+^   3 month                     −

Hypo, hypoglycemia; IHC, immunohistochemistry; N/A, not available; F, female; M, male; L, left; R, right; RLig, round ligament; TACE, transarterial chemoembolization; HRT, hormone replacement therapy; MWA, microwave ablation; CD, cluster of differentiation; V vimentin; Bcl-2, B-cell lymphoma 2; STAT6, signal transducer and activator of transcription 6; NSE, neuron specific enolase; SMA, smooth muscle actin; PR, progestrone receptor.

###### 

Data on reported ex situ liver autotransplantation cases.

  First author, year           Age, years   Sex   Diagnosis                         Characteristics of lesion/contraindication to traditional resection               Follow-up                                                                                (Refs.)
  ---------------------------- ------------ ----- --------------------------------- --------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ----------------------
  Pichlmayr *et al*, 1988      40           N/A   Metastatic leiomyosarcoma         Bilateral liver metastases                                                        N/A                                                                                      ([@b4-ol-0-0-9693])
  Yagyu *et al*, 1994          N/A          N/A   Intrahepatic cholangiocarcinoma   Involved the confluence of the 3 main hepatic veins and the retrohepatic IVC      No recurrence at 8 months                                                                ([@b78-ol-0-0-9693])
  Hemming and Cattral, 1999    50           M     Colorectal liver metastases       A single lesion in the caudate lobe involved the origin of all 3 hepatic veins    N/A                                                                                      ([@b76-ol-0-0-9693])
  Lodge *et al*, 2000          55           F     Colorectal liver metastases       Involvement of IVC and segments 1, 2, 3, 4a and 8                                 Post-operative chemotherapy, 30 months survival                                          ([@b79-ol-0-0-9693])
                                                  Colorectal liver metastases       Involvement of segments 2 and 4--8                                                Succumbed from complications of renal and respiratory failure on post-operative day 15   
                                                  Colorectal liver metastases       17×15 cm mass involving segments 1, 2 and 4--8                                    Alive at 5 months                                                                        
                                                  Colorectal liver metastases       17×13 cm mass involving segments 1, 2, 4--8                                       Alive at 5 months                                                                        
  Oldhafer *et al*, 2000       40           F     Metastatic leiomyosarcoma         Involvement of segments 2, 3 and 5--8                                             Succumbed at 36 months due to tumor recurrence                                           ([@b72-ol-0-0-9693])
                               46           F     Metastatic colon cancer           Involvement of segments 5--7                                                      Succumbed at 13 months due to tumor recurrence                                           
                               52           M     Klatskin\'s tumor                 Required right hepatic trisegmentectomy                                           Succumbed at 13 months due to tumor recurrence                                           
                               58           M     Metastatic colon cancer           Metastatic colon cancer infiltrating the IVC                                      Succumbed at 44 days due to sepsis and hepatic insufficiency                             
                               30           F     Focal nodular hyperplasia         Large FNH in segment 4 with compression                                           Alive at 9 years of the IVC                                                              
                               57           M     Metastatic colon cancer           Infiltration of RHV requiring extended left hemihepatectomy                       Succumbed at 21 months due to tumor recurrence                                           
                               48           F     Klatskin\'s tumor                 Klatskin\'s tumor requiring extended left hemihepatectomy                         Succumbed on post-operative day 50 due to sepsis                                         
                               62           M     Klatskin\'s tumor                 Tumor invading left and right portal veins                                        Succumbed on post-operative day 113 due to sepsis                                        
                               55           F     Klatskin\'s tumor                 Klatskin\'s tumor requiring right hepatic trisegmentectomy                        Succumbed on post-operative day 35 due to sepsis                                         
                               35           M     HCC                               HCC requiring resection of segments 1--4                                          Lost to follow-up and wedge 6                                                            
                               43           M     HCC                               HCC requiring resection of segments 5 and 6                                       Succumbed at 25 months due to tumor recurrence                                           
                               67           M     Metastatic colon cancer           Lesions requiring resection of segments 1-4b and wedge 6--7                       Succumbed at 2 months due to intracerebral bleed                                         
                               53           M     Metastatic colon cancer           Lesions requiring resection of segments 1 and 4--8                                Succumbed at 2 months due to sepsis                                                      
                               54           F     Focal nodular hyperplasia         Lesions requiring resection of segments 1, 4, 5 and 7                             Alive at 5 years                                                                         
                               55           M     Metastatic colon cancer           Lesions requiring resection of segments 1 and 4                                   Succumbed at 15 months due to tumor recurrence                                           
                               55           F     Metastatic leiomyosarcoma         Lesion requiring resection of segments 2-4b and wedge 5                           Succumbed at 13 months due to tumor recurrence                                           
                               52           M     Metastatic colon cancer           Lesions requiring resection of segments 1, 5 and 8                                Succumbed at 36 months due to tumor recurrence                                           
                               40           F     Metastatic leiomyosarcoma         Lesions requiring resection of segments 1, 4--8 and wedge 2--3                    Succumbed at 18 months due to tumor recurrence                                           
                               52           M     Metastatic colon cancer           Lesions requiring resection of segments 1 and partial 4                           Succumbed on post-operative day 14 due to pneumonia                                      
                               52           M     Cholangiocarcinoma                Lesion requiring resection of segments 1--5 and wedge 8                           Succumbed on post-operative day 41 due to sepsis                                         
                               39           M     HCC                               Lesion requiring resection of segments 1--4 and partial 8                         Succumbed on post-operative day 23 due to sepsis                                         
                               71           M     Metastatic colon cancer           Lesions requiring resection of segments 1 and 5--8                                Alive after 13 months                                                                    
  Chui *et al*, 2003           26           F     Cholangiocarcinoma                2.3-cm hilar mass involving the portal vein confluence and right hepatic artery   Alive with no recurrence on MRI at 17 months                                             ([@b80-ol-0-0-9693])
  Gruttadauria *et al*, 2005   41           M     Cholangiocarcinoma                14×12 cm mass encompassing segments 4a, 4b and 5 with RHA involvement             Recurrence at 10 months and 13 months, receiving radiation; still alive at 23 months     ([@b81-ol-0-0-9693])
                               58           M     Leiomyosarcoma of the IVC         Third attempt at resection                                                        Discharged on post-operative day 10; long-term outcome N/A                               
  Ikegami *et al*, 2007        39           F     Giant hepatic hemangiomas         4 large hemangiomas in segments 1--3, caudal 4 and 6--7                           Normal liver function with a regenerated liver graft at 8 months                         ([@b75-ol-0-0-9693])
  Sugimachi *et al*, 2010      17           F     HCC                               18×12 cm lesion involving IVC, RHV and first left branch of portal vein           Alive 28 months after resection; no post-operative chemotherapy                          ([@b82-ol-0-0-9693])
  Gringeri *et al*, 2012       38           F     Hepatic metastasis from           2.5 cm lesion in left lobe and 2.7-cm lesion in pancreatoblastoma                 Alive after 8 months right lobe involving MHV and RHV                                    ([@b83-ol-0-0-9693])
  Zhang *et al*, 2012          60           F     Hepatic hemangiomas               Lesions requiring resection of segments 4--8                                      Alive at 22 months                                                                       ([@b74-ol-0-0-9693])
                               64           M     Cholangiocarcinoma                Lesions requiring resection of segments 1--4                                      Alive at 17 months                                                                       
                               55           M     Cholangiocarcinoma                Lesions requiring resection of segments 1, 5, 7 and 8                             Succumbed on post-operative day 1 due to liver and renal failure                         
  Wen *et al*, 2013            67           M     HCC                               18×12 cm lesion at the confluence of the LHV, MHV and IVC                         Alive at 28 months, no recurrence                                                        ([@b73-ol-0-0-9693])
                               71           M     HCC                               18×13 cm lesion at the confluence of the V7/RHV into the IVC                      Alive at 26 months, recurrence treated with RFA                                          
                               60           M     HCC                               5.8×6.8 cm lesion centrally located, involving the RHV and PV                     Alive at 23 months, recurrence treated with TACE                                         
  Baker *et al*, 2015          66           F     Extensive cholangiocarcinoma      Lesions involving all 3 hepatic veins                                             Alive at 3 months                                                                        ([@b6-ol-0-0-9693])
  Vicente *et al*, 2017        51           M     Cholangiocarcinoma                Lesions involving retrohepatic vena cava together with the 3 hepatic veins        Alive at 36 months                                                                       ([@b77-ol-0-0-9693])
  Present case                 32           F     Solitary fibrous tumor            Lesions involving the right and left hepatic arteries                             Alive at 3 month                                                                         N/A

F, female; M, male; FNH, focal nodular hyperplasia; HCC, hepatocellular carcinoma; IVC, inferior vena cava; LHV, left hepatic vein; MHV, middle hepatic vein; PV, portal vein; RFA, radiofrequency ablation; RHV, right hepatic vein; RHA, right hepatic artery; TACE, transarterial chemoembolization; V7, hepatic vein branch draining segment VII of the liver.
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